"Digestive Healthcare for the Whole Family"

During the past decade, Atlanta Gastroenterology Associates conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 33 clinical trials were completed, i.e. on average, 78.6% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 16 clinical trials were completed. i.e. 145.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Atlanta Gastroenterology Associates" #1 sponsor was "Bristol-Myers Squibb" with 9 trials, followed by "Celgene" with 9 trials sponsored, "Gilead Sciences" with 9 trials sponsored, "Takeda" with 6 trials sponsored and "Abbott" with 6 trials sponsored. Other sponsors include 68 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Atlanta Gastroenterology Associates" #1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Cedars-Sinai Medical Center" with 2 trials as a collaborator, "Crohn's and Colitis Foundation" with 2 trials as a collaborator and "Elan Pharmaceuticals" with 2 trials as a collaborator. Other collaborators include 25 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "Atlanta Gastroenterology Associates" are "Crohn's Disease" (33 trials), "Ulcerative Colitis" (25 trials), "Crohn Disease" (12 trials), "Chronic Hepatitis C" (8 trials) and "Hepatitis C" (5 trials). Many other conditions were trialed in "Atlanta Gastroenterology Associates" in a lesser frequency.

Most popular intervention types in "Atlanta Gastroenterology Associates" are "Drug" (91 trials), "Other" (13 trials), "Biological" (7 trials), "Device" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Ribavirin" (7 trials), "Etrasimod" (4 trials), "Etrolizumab" (4 trials) and "Ozanimod" (4 trials). Other intervention names were less common.

The vast majority of trials in "Atlanta Gastroenterology Associates" are 109 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Atlanta Gastroenterology Associates". undefined are not yet recruiting, 10 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 81 completed trials in Atlanta Gastroenterology Associates, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Atlanta Gastroenterology Associates, 3 "Phase 1" clinical trials were conducted, 42 "Phase 2" clinical trials and 53 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".

Atlanta Gastroenterology Associates has several departments that took part in Clinical trials: "Atlanta Gastroenterology Associates" - 7 trials, "Advanced Gastroenterology Associates" - 2 trials